TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat…...
2022 V-RED Winners
There’s something unique about the Vasculitis Foundation’s (VF’s) 2022 Recognizing Excellence in Diagnostics (V-RED) award program: We have two winners who tied for first place and two winners who received honorable mentions. Now in its ninth year, the V-RED award program calls on patients worldwide to nominate a medical professional…...
VF Board of Directors Welcomes Nona Bear
Nona is a nationally known advocate of healthcare reform and champion of seniors’ issues. Originally an academic who served on the faculties of several Washington-area universities including American, Howard, and George Mason, she was hired to establish a continuing education program at the U.S. Soldiers’ and Airmen’s Home, a facility…...
